Coya Therapeutics Plunges 12.5% on Study Results

On April 23, 2025, Coya Therapeutics experienced a significant drop of 12.5% in pre-market trading, marking a notable decline in its stock performance.

Coya Therapeutics recently announced the publication of study results for COYA 303, an investigational biologic that combines low-dose interleukin 2 (LD IL-2) with a GLP-1 receptor agonist (GLP-1RA). The study revealed that COYA 303 enhances the survival of regulatory T cells (Tregs), providing superior protection against cell death. This breakthrough could have significant implications for the treatment of autoimmune diseases and other conditions where Treg function is compromised.

The publication of these study results has garnered attention from the scientific community, highlighting the potential of COYA 303 as a revolutionary biologic. The enhanced Treg cell survival and function demonstrated in the study suggest that COYA 303 could offer a more effective therapeutic approach compared to existing treatments. This development is likely to influence investor sentiment and could impact the company's future stock performance.